Ritonavir-boosted protease inhibitors in HIV therapyHULL, Mark W; MONTANER, Julio S. G.Annals of medicine (Helsinki). 2011, Vol 43, Num 5-6, pp 375-388, issn 0785-3890, 14 p.Article

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimenHARRIS, Marianne; LARSEN, Gerene; MONTANER, Julio S. G et al.AIDS (London). 2008, Vol 22, Num 10, pp 1224-1226, issn 0269-9370, 3 p.Article

Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor AssayLIMA, Viviane; HARRIGAN, Richard; MONTANER, Julio S. G et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 1, pp 3-6, issn 1525-4135, 4 p.Article

Exacerbation of depression associated with starting raltegravir : a report of four casesHARRIS, Marianne; LARSEN, Gerene; MONTANER, Julio S. G et al.AIDS (London). 2008, Vol 22, Num 14, pp 1890-1892, issn 0269-9370, 3 p.Article

Response to Lancaster et al. generalizability and scalability of HIV 'treatment as prevention'NOSYK, Bohdan; MONTANER, Julio S. G.AIDS (London). 2013, Vol 27, Num 14, pp 2319-2320, issn 0269-9370, 2 p.Article

Delavirdine increases drug exposure of ritonavir-boosted protease inhibitorsHARRIS, Marianne; ALEXANDER, Chris; O'SHAUGHNESSY, Michael et al.AIDS (London). 2002, Vol 16, Num 5, pp 798-799, issn 0269-9370Article

Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: A case seriesDELGADO, Juan; HARRIS, Marianne; TESIOROWSKI, Alicja et al.Clinical infectious diseases. 2001, Vol 33, Num 12, pp 2072-2074, issn 1058-4838Article

Changing Global Epidemiology of Pulmonary Manifestations of HIV/AIDSHULL, Mark W; PHILLIPS, Peter; MONTANER, Julio S. G et al.Chest (American College of Chest Physicians). 2008, Vol 134, Num 6, pp 1287-1298, issn 0012-3692, 12 p.Article

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis CBRAITSTEIN, Paula; PALEPU, Anita; DIETERICH, Douglas et al.AIDS (London). 2004, Vol 18, Num 17, pp 2221-2234, issn 0269-9370, 14 p.Article

Optimising HIV Treatment - Building on Experience: based on a Symposium held Friday 15 March 2002, Seville, SpainCOOPER, David; LANGE, Joep M. A; MONTANER, Julio S. G et al.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 34, issn 1525-4135, 103 p., SUP1Conference Proceedings

The T cell receptor vβ repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infectionGRANT, Michael; PARDOE, Ingrid; WHALEY, Mark et al.AIDS (London). 2002, Vol 16, Num 2, pp 287-290, issn 0269-9370Article

A compromise strategy for patients with multiple drug failureMONTANER, Julio S. G; HARRIS, Marianne; HARRIGAN, Richard et al.AIDS (London). 2001, Vol 15, Num 18, issn 0269-9370, p. 2470Article

Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysisWERB, Daniel; MILIS, Edward J; MONTANER, Julio S. G et al.Lancet. Infectious diseases (print). 2010, Vol 10, Num 7, pp 464-469, issn 1473-3099, 6 p.Article

Transient neuropathy after needle-free injection outside of recommended sitesHARRIS, Marianne; LARSEN, Gerene; VALYI, Monica et al.AIDS (London). 2006, Vol 20, Num 5, pp 784-785, issn 0269-9370, 2 p.Article

Intracellar carbovir triphosphate levels in patients taking abacavir once a dayHARRIS, Marianne; BACK, David; KEWN, Sean et al.AIDS (London). 2002, Vol 16, Num 8, pp 1196-1197, issn 0269-9370Article

A review of barriers and facilitators of HIV treatment among injection drug usersWOOD, Evan; KERR, Thomas; TYNDALL, Mark W et al.AIDS (London). 2008, Vol 22, Num 11, pp 1247-1256, issn 0269-9370, 10 p.Article

Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infectionCHAN, Kenny C. W; GALLI, Richard A; MONTANER, Julio S. G et al.AIDS (London). 2003, Vol 17, Num 8, pp 1256-1258, issn 0269-9370, 3 p.Article

Tipranavir: A protease inhibitor from a new class with distinct antiviral activityYENI, Patrick.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 34, pp S91-S94, issn 1525-4135, SUP1Conference Paper

Rate of detoxification service use and its impact among a cohort of supervised injecting facility usersWOOD, Evan; TYNDALL, Mark W; ZHANG, Ruth et al.Addiction (Abingdon. Print). 2007, Vol 102, Num 6, pp 916-919, issn 0965-2140, 4 p.Article

Efficacy and durability of nevirapine in antiretroviral-experienced patientsHARRIS, Marianne.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 34, pp S53-S58, issn 1525-4135, SUP1Conference Paper

Future treatment perspectivesVELLA, Stefano.Journal of acquired immune deficiency syndromes (1999). 2003, Vol 34, pp S95-S100, issn 1525-4135, SUP1Conference Paper

Potential Impact of the US President's Emergency Plan for AIDS Relief on the Tuberculosis/HIV Coepidemic in Selected Sub-Saharan African CountriesLIMA, Viviane D; GRANICH, Reuben; PHILLIPS, Peter et al.The Journal of infectious diseases. 2013, Vol 208, Num 12, pp 2075-2084, issn 0022-1899, 10 p.Article

Incidence and determinants of initiation into cocaine injection and correlates of frequent cocaine injectorsLLOYD-SMITH, Elisa; WOOD, Evan; LI, Kathy et al.Drug and alcohol dependence. 2009, Vol 99, Num 1-3, pp 176-182, issn 0376-8716, 7 p.Article

When to initiate antiretroviral therapy in HIV-1-infected adults : a review for clinicians and patientsWOOD, Evan; HOGG, Robert S; HARRIGAN, P. Richard et al.Lancet. Infectious diseases (print). 2005, Vol 5, Num 7, pp 407-414, issn 1473-3099, 8 p.Article

Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?WOOD, Evan; HOGG, Robert S; YIP, Benita et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 38, Num 3, pp 289-295, issn 1525-4135, 7 p.Article